roidism. As Asher's graphic term "myxoedematous madness"'5 indicates, the earlier descriptions based on clinically obvious cases of myxoedema16 17 stressed the occurrence of florid psychotic manifestations, depression being mentioned only parenthetically. In our relatively unselected cases depression totally overshadowed manifestations of this type.
Introduction
The management of status epilepticus has been transformed in recent years by the introduction of intravenous diazepam and thiopentone, which have largely replaced parenterally administered phenytoin, phenobarbitone, and paraldehyde. Nevertheless, some patients with status epilepticus fail to respond to these drugs. We have found chlormethiazole (Heminevrin) to be valuable in these cases. We report here its use in nine episodes of status epilepticus in eight patients seen over two years.
Chlormethiazole is a derivative of the thiazole nucleus of thiamine (vitamin BJ). It intravenous infusion at the rate of 500 ml over six to eight hours (0 7 g -0 5 g/h) to seven of the eight patients. The eighth (case 3) was given chlormethiazole 0-5 g every three hours by mouth (table II) .
Results of Chlormethiazole Treatment
Seizures stopped in all patients within six hours of starting chlormethiazole (table II) , but in cases 1 and 2 it had to be continued for three weeks since any reduction in the rate of infusion precipitated further fits. Assisted ventilation was not needed in either case when chlormethiazole was substituted for thiopentone. After three weeks, chlormethiazole 1 g three-hourly by mouth was substituted for intravenous therapy in case 1 and the patient remained free from fits until she died. One patient (case 4 a) was successfully controlled on intravenous chlormethiazole but developed a severe thrombophlebitis after 24 hours. Treatment was changed to chlormethiazole 0 75 g by mouth every two hours. She remained free from fits. In case 3 satisfactory control was achieved with chlormethiazole 0 5 g given through a nasogastric tube every three hours from the beginning. In cases 5 and 8 status epilepticus recurred after four and three days respectively, though the dose of chlormethiazole had not been changed. A bolus of chlormethiazole 1-6 g given over one hour had no effect in case 8 and the patient responded only to ethosuximide. There are several reports of the efficacy of intravenous chlormethiazole in status epilepticus. 9-12 In all except one doses of between 1-2 g and 3 g were given as a bolus and repeated at intervals of up to four hours. The reports are uniformly enthusiastic about the results, but varying degrees of depression of the level of consciousness and respiration were encountered. Houdart and Laborit 11 used a similar regimen to ours (03 g/h as a constant infusion) and their patients did not have these side effects. More recently Manhire and Espir" described a case of status epilepticus in which chlormethiazole controlled the fits but only at a rate of infusion (1-5 g/h) which resulted in coma. '4 We obtained satisfactory results with a rate of infusion of 0-5-0 7 g/h without serious impairment of consciousness or depression of respiration.
We think that chlormethiazole deserves wider recognition as an effective therapeutic agent in the management of status epilepticus.
